Matthew B Gretzer
- Associate Professor, (Clinical Scholar Track)
In addition to general urology, I specialize in the management of urethral stricture disease and am one of a few Arizona urologists that routinely perform complex urethral reconstruction (urethroplasty). In addition, I have expertise in the management of erectile dysfunction, post-prostatectomy incontinence, and complex urinary diversion and reconstruction following prostate and bladder cancer surgery.
- M.D. Doctor of Medicine
- University of Texas Health Science Center, San Antonio, Texas, United States
- B.A. Biological Sciences with Honors
- University of Colorado, Boulder, Colorado, United States
- UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE (2013 - Ongoing)
- Banner University Medical Center South (2006 - 2009)
- Banner University Medical Center South (2006 - 2009)
- University of Arizona, College of Medicine (2005 - Ongoing)
- University of Arizona College of Medicine, Tucson, Arizona (2005 - 2013)
- Johns Hopkins Brady Urological Institute (2004 - 2005)
- University of Texas, MD Anderson Cancer Center (1992 - 1994)
- Alpha Omega Alpha Honor Medical Society
- University of Texas at San Antonio, TX, Summer 1997
- Microscopic Anatomy Honors Award
- University of Texas Health Science Center, San Antonio, TX, Summer 1995
- Golden Key National Honor Society
- University of Colorado at Boulder, CO, Summer 1991
- Undergraduate Research Opportunity Award
- University of Colorado at Boulder, CO, Summer 1990
- Urology Reviewer Recognition
- Elsevier reviews, Winter 2018
- AUA Leadership Program
- American Urological Association, Spring 2018
- RESIDENT TEACHING AWARD
- UNIVERSITY OF ARIZONA UROLOGY RESIDENTS, Summer 2014
- UNIVERSITY OF ARIZONA UROLOGY RESIDENTS, Summer 2010
- Resident Teaching Award
- University of Arizona Division of Urology, Summer 2014
- Urology Resident Teaching Award
- University of Arizona Division of Urology, Summer 2010
- American College of Surgeons, Summer 2008
- American Board of Urology, Summer 2007
- Gerald P. Murphy Scholar in Prostate Cancer
- 2004 Annual Meeting of the American Urological Association, Summer 2004
- 2002 Annual Meeting of the American Urological Association, Summer 2002
- AUA/ACMI Essay Contest; Laboratory Research 3rd Prize
- 2003 Annual Meeting of the American Urological Association, Summer 2003 (Award Finalist)
Licensure & Certification
- MARYLAND MEDICAL LICENCE, MARYLAND MEDICAL BOARD (2003)
- DIPLOMATE AMERICAN BOARD OF UROLOGY, AMERICAN BOARD OF UROLOGY (2007)
- ARIZONA MEDICAL LICENCE, ARIZONA MEDICAL BOARD (2005)
- FELLOW, AMERICAN COLLEGE OF SURGEONS, AMERICAN COLLEGE OF SURGEONS (2008)
- DIPLOMATE AMERICAN BOARD OF UROLOGY, AMERICAN BOARD OF UROLOGY (2015)
PATIENT REPORTED OUTCOMES IN GU RECONSTRUCTION. DEVELOPMENT OF NEW DIAGNOSTIC TOOLS TO ASSESS THE FLUID DYNAMICS OF VOIDING.REVIEW OF OUTCOMES IN GU TRAUMA MANAGEMENT
RESIDENT TEACHING IN CLINIC AND OPERATING ROOM. UROLOGIC CORE CURRICULUM AND ORAL BOARD REVIEW.
No activities entered.
- Gretzer, M. B., Partin, A. W., Kavoussi, L. R., Novick, A. C., & Peters, C. A. (2007). Prostate Cancer Tumor Markers. In Campbell's-Walsh Urology, 9th ed.(pp 2896-2911).
- Gretzer, M. B. (2006). Benign Prostatic Hyperplasia. In Brady Urology Manual, 1st Ed.(pp 71-84).
- Gretzer, M. B., & Wright, E. J. (2004). Use of Cadaveric Fascia Lata Allograft for Pubovaginal Slings. In Female Urology, Urogynecology, and Voiding Dysfunction(pp 353-361). Marcel Dekker, New York.
- Gretzer, M. B., Partin, A. W., & Chan, D. Y. (2004). Lower Urinary Tract Symptoms and BPH. In Minimally Invasive Urologic Surgery(pp 351-373). Taylor & Francis, London & New York.
- Gretzer, M. B., & Partin, A. W. (2003). PSA and PSA Molecular Derivatives. In Campbell's Update(pp 3-12).
- Gretzer, M. B., Yang, D. J., Kuang, L. R., & Cherif, A. (1995). Radiolabeled Tamoxifen. In View of Imaging Centers(pp 513-526). Plenum Publishing Corp., New York, NY.
- Pollock, G. R., & Gretzer, M. (2020). AUTHOR REPLY. Urology, 137, 209.
- Pollock, G. R., Zeng, J., & Gretzer, M. (2020). Partial Penectomy for Dry Penile Gangrene in a Patient With Penile Calciphylaxis. Urology, 141, e3-e4.More infoPenile calciphylaxis is a difficult urologic condition to manage. First described by Wood et al in 1997, penile calciphylaxis is a rare cause of penile gangrene. One study found the overall mortality rate associated with penile calciphylaxis to be 64%, with a mean time to death of 2.5 months. Additionally, no statistically significant difference in survival has been seen between patients treated with penectomy and those treated nonoperatively. We report a case of penile calciphylaxis in a patient treated with partial penectomy with scrotoplasty who has survived greater than 1 year without any complication or progression of disease.
- Nash, S., Aboseif, S., Gilling, P., Gretzer, M., Samowitz, H., Rose, M., Slutsky, J., Siegel, S., & Tu, L. M. (2019). Four-year follow-up on 68 patients with a new post-operatively adjustable long-term implant for post-prostatectomy stress incontinence: ProACT™. Neurourology and urodynamics, 38(1), 248-253.More infoThis paper presents 4-year follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The study evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI).
- Pollock, G. R., Bergersen, A., Chaus, F. M., & Gretzer, M. (2019). Pelvic Hematoma Following UroLift procedure for BPH. Urology, 133, e3-e4.More infoWe present an interesting complication following the UroLift procedure: the development of a pelvic hematoma. This patient presented to the emergency department with pelvic pain, penile ecchymosis, and edema on postoperative day 4 following his UroLift procedure. A computed tomography scan revealed that his symptoms were due to the formation of a large pelvic hematoma. To our knowledge, pelvic hematoma formation following UroLift is a unique complication not previously described in the literature.
- DeLay, K. J., Haney, N. M., Chiang, J., Stewart, C., Yafi, F. A., Angermeier, K., Wood, H., Boone, T., Kavanagh, A. G., Gretzer, M., Boyd, S., Loh-Doyle, J. C., & Hellstrom, W. J. (2018). Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional, Retrospective Analysis. Urology, 113, 160-165.More infoTo determine if the timing of radiation therapy on artificial urinary sphincter (AUS) impacts complication rates, revision rates, and number of pads per day after placement.
- Nash, S., Aboseif, S., Gilling, P., Gretzer, M., Samowitz, H., Rose, M., Slutsky, J., Siegel, S., & Tu, L. M. (2018). Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial. Neurourology and Urodynamics, 37(8), 2854-2859. doi:10.1002/nau.23802More infoThis paper presents 18-month follow-up results for patients enrolled in apivotal study conducted to support an FDA premarket approval application (PMAA).The trial evaluated the safety and efficacy of the ProACT Adjustable ContinenceTherapy for the treatment of post-prostatectomy stress urinary incontinence (SUI).
- Nash, S., Aboseif, S., Gilling, P., Gretzer, M., Samowitz, H., Rose, M., Slutsky, J., Siegel, S., & Tu, L. M. (2018). Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial. Neurourology and urodynamics, 37(8), 2854-2859.More infoThis paper presents 18-month follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The trial evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI).
- DeLay, K., Haney, N. M., C, J., Stewart, C., Yafi, F. A., Abgermeier, K., Wood, H., Boone, T., Kavanagh, A. G., Gretzer, M., Boyd, S., Loh-Doyle, J. C., & Hellstrom, W. J. (2018). Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional Analysis. Urology. doi:10.1016/j.urology.2017.11.041
- Gretzer, M. (2017). Three-Year Follow-Up on 81 Patients with a New Post-Operatively Adjustable Long-Term Implant for Post-Prostatectomy Stress Incontinence: ProACT™. Neurology and Urodynamics, 5.
- Michalak, J., Edward, B., Jonathan, W., Gretzer, M., Twiss, C. O., & Funk, J. (2017). The Impact of Surgical Masks on the Rate of Postoperative Urinary Tract Infection after Cystoscopy and Ureteroscopy. Journal of Urology.
- Dyer, A., Sadow, P. M., Bracamonte, E., & Gretzer, M. (2014). Immunoglobulin G4-related Retroperitoneal Fibrosis of the Pelvis. Reviews in urology, 16(2), 92-4.More infoRetroperitoneal fibrosis (RPF) is a rare disease characterized by the replacement of normal tissue with fibrosis and/or inflammation. In this case, a 68-year-old man presented with RPF in the pelvis, a rare location for this disease. Biopsies were performed, which showed elevated levels of C-reactive protein, erythrocyte sedimentation rate, and, most importantly, immunoglobulin G4 (IgG4). It has been postulated that IgG4-related sclerosing disease is a systemic disease. Treatment has been successful with systemic corticosteroids.
- Nguyen, M. M., Ahmann, F. R., Nagle, R. B., Hsu, C., Tangrea, J. A., Parnes, H. L., Sokoloff, M. H., Gretzer, M. B., & Chow, H. S. (2012). Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer prevention research (Philadelphia, Pa.), 5(2), 290-8.More infoCompelling preclinical and pilot clinical data support the role of green tea polyphenols in prostate cancer prevention. We conducted a randomized, double-blind, placebo-controlled trial of polyphenon E (enriched green tea polyphenol extract) in men with prostate cancer scheduled to undergo radical prostatectomy. The study aimed to determine the bioavailability of green tea polyphenols in prostate tissue and to measure its effects on systemic and tissue biomarkers of prostate cancer carcinogenesis. Participants received either polyphenon E (containing 800 mg epigallocatechin gallate) or placebo daily for 3 to 6 weeks before surgery. Following the intervention, green tea polyphenol levels in the prostatectomy tissue were low to undetectable. Polyphenon E intervention resulted in favorable but not statistically significant changes in serum prostate-specific antigen, serum insulin-like growth factor axis, and oxidative DNA damage in blood leukocytes. Tissue biomarkers of cell proliferation, apoptosis, and angiogenesis in the prostatectomy tissue did not differ between the treatment arms. The proportion of subjects who had a decrease in Gleason score between biopsy and surgical specimens was greater in those on polyphenon E but was not statistically significant. The study's findings of low bioavailability and/or bioaccumulation of green tea polyphenols in prostate tissue and statistically insignificant changes in systemic and tissue biomarkers from 3 to 6 weeks of administration suggests that prostate cancer preventive activity of green tea polyphenols, if occurring, may be through indirect means and/or that the activity may need to be evaluated with longer intervention durations, repeated dosing, or in patients at earlier stages of the disease.
- Sroka, I. C., Anderson, T. A., McDaniel, K. M., Nagle, R. B., Gretzer, M. B., & Cress, A. E. (2010). The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. Journal of cellular physiology, 224(2), 283-8.More infoMetastasizing prostate tumor cells invade along nerves innervating the encapsulated human prostate gland in a process known as perineural invasion. The extracellular matrix laminin class of proteins line the neural route and tumor cells escaping from the gland express the laminin binding integrin alpha6beta1 as a prominent cell surface receptor. Integrin alpha6beta1 promotes aggressive disease and supports prostate tumor cell metastasis to bone. Laminins and their integrin receptors are necessary for the development and maintenance of the peripheral nervous system, indicating the potential role for integrin receptors in directing prostate tumor cell invasion on nerves during perineural invasion.
- Malik, G., Rojahn, E., Ward, M. D., Gretzer, M. B., Partin, A. W., Semmes, O. J., & Veltri, R. W. (2007). SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression. The Prostate, 67(14), 1565-75.More infoWe recently demonstrated the protein expression profiling of Dunning rat tumor cell lines of varying metastatic potential (G (0%), AT-1 ( approximately 20%), and MLL (100%)) using SELDI-TOF-MS. As a parallel effort, we have been pursuing the identification of the protein(s) comprising the individual discriminatory "peaks" and evaluating their utility as potential biomarkers for prostate cancer progression.
- Gretzer, M. B., & Copeland, D. (2006). Deep Venous Thrombosis: Evidence-Based Prevention Strategies. Contemporary Urology, 48-54.
- Gretzer, M. B., Chan, D. W., van Rootselaar, C. L., Rosenzweig, J. M., Dalrymple, S., Mangold, L. A., Partin, A. W., & Veltri, R. W. (2004). Proteomic Analysis of Dunning Prostate Cancer Cell Lines with Variable Metastatic Potential Using SELDI-TOF. The Prostate, 325-331.
- Gretzer, M. B., & Partin, A. W. (2003). 54-year-old male with high-grade prostatic intraepithelial neoplasia on prostate biopsy. Reviews in urology, 5(1), 45-8.
- Gretzer, M. B., & Partin, A. W. (2003). Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. Reviews in urology, 5(2), 111-7.
- Gretzer, M. B., & Partin, A. W. (2003). Molecular Forms of PSA: What does the future hold? Antigen's Various Molecular Forms may Improve PSA Tests' Clinical Utility. Urology Times, 42-43.
- Gretzer, M. B., & Partin, A. W. (2003). PSA markers in prostate cancer detection. The Urologic clinics of North America, 30(4), 677-86.More infoThe PSA revolution that has occurred over the previous 2 decades has positively impacted the detection and treatment of men with prostate cancer. Although methods to improve specificity have shown promise (eg, PSAD, age-specific PSA, and PSA velocity), meaningful interpretation has yet to be uniformly accepted within clinical practice. The identification of other molecular forms of PSA within serum has led to a new era in PSA markers. Initial application employing %fPSA has provided improved discrimination between benign and malignant prostatic disease; however, questions remain regarding the ultimate threshold value. The discovery of various free forms of PSA--such as proPSA, BPSA, and iPSA--also have introduced the potential for improved specificity in detection. Although early results are encouraging, further evaluation is anticipated. The development of improved methods to detect and measure cPSA has demonstrated provocative results, and exhibits the potential to replace PSA as a standard diagnostic test in cancer screening.
- Gretzer, M. B., Partin, A. W., Chan, D. W., & Veltri, R. W. (2003). Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). Reviews in urology, 5(2), 81-9.More infoDuring the last two decades, biomarker research has benefited from the introduction of new proteomic analytical techniques. In this article, we review the application of surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectroscopy in urologic cancer research. After reviewing the literature from MEDLINE on proteomics and urologic oncology, we found that SELDI-TOF is an emerging proteomic technology in biomarker discovery that allows for rapid and sensitive analysis of complex protein mixtures. SELDI-TOF is a novel proteomic technology that has the potential to contribute further to the understanding and clinical exploitation of new, clinically relevant biomarkers.
- Gretzer, M. B., & Partin, A. W. (2002). PSA Levels and the Probability of Prostate Cancer on Biopsy. European Urology, 21-27.
- Gretzer, M. B., Epstein, J. I., Pound, C. R., Walsh, P. C., & Partin, A. W. (2002). Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology, 60(6), 1034-9.More infoTo evaluate the influence of preoperative prostate-specific antigen (PSA), biopsy Gleason sum, and prostate biopsy quantitative histologic findings on the probability of biochemical failure in an attempt to identify criteria to substratify Stage T1c prostate cancer more accurately.
- Gretzer, M. B., Trock, B. J., Han, M., & Walsh, P. C. (2002). A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. The Journal of urology, 168(4 Pt 1), 1419-22.More infoThe use of prostate specific antigen (PSA) to indicate biochemical failure has become an accepted procedure to measure the effectiveness of therapy. Because long-term randomized studies comparing radiation modalities to radical prostatectomy are not available, use of biochemical recurrence as a surrogate measure of efficacy is increasing. Unfortunately, the definition of failure is not uniform among therapies. We evaluate how the American Society for Therapeutic Radiation and Oncology (ASTRO) criteria affect the interpretation of failure when applied to radical prostatectomy.
- Yang, D. J., Wallace, S., Cherif, A., Li, C., Gretzer, M. B., Kim, E. E., & Podoloff, D. A. (1995). Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology, 194(3), 795-800.More infoTo develop a hydrophilic ligand to image tumor hypoxia at positron emission tomography (PET).
- Gretzer, M. B., Yang, D. J., Li, C., Nikifarow, S., Kuang, L. R., Lopez, M. S., Vargas, K., & Wallace, S. (1994). Poly (benzyl-1-glutamate): Diagnostic and Therapeutic Potential. Journal of Pharmacy Sciences, 328-331.
- Yang, D. J., Li, C., Kuang, L. R., Price, J. E., Buzdar, A. U., Tansey, W., Cherif, A., Gretzer, M., Kim, E. E., & Wallace, S. (1994). Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life sciences, 55(1), 53-67.More infoTamoxifen binds to estrogen receptors (ERs) and prevents breast cancer cell proliferation. This study is aimed at developing a ligand for imaging ER (+) breast tumors by positron emission tomography (PET) or single photon emission computed tomography (SPECT). [18F]-Labeled tamoxifen analogue ([18F]FTX) was prepared in 30-40% yield and [131I]-labeled tamoxifen analogue ([131I]ITX) was prepared in 20-25% yield. In mammary tumor-bearing rats, the biodistribution of [18F]FTX at 2 h showed a tumor uptake value (% injected dose/gram tissue) of 0.41 +/- 0.07; when rats were pretreated with diethylstilbestrol (DES), the value changed to 0.24 +/- 0.017. [131I]ITX at 6 h showed a tumor uptake value of 0.26 +/- 0.166; when rats were pretreated with DES, the value changed to 0.22 +/- 0.044. Priming tumor-bearing rats with estradiol, a tumor uptake value for [131I]ITX was increased to 0.48 +/- 0.107 at 6 h. In the [3H]estradiol receptor assay, tumors had a mean estrogen receptor density of 7.5 fmol/mg of protein. In gamma scintigraphic imaging studies with [131I]ITX, the rabbit uterus uptake can be blocked by pretreatment with DES. Both iodo-tamoxifen and tamoxifen reduced ER(+) breast tumor growth at the dose of 50 micrograms in tumor-bearing mice. The findings indicate that tamoxifen analogue uptake in tumors occurs via an ER-mediated process. Both analogues should have potential for diagnosing functioning ER(+) breast cancer.
- Gretzer, M. B. (2010, July). Prostate Cancer 101. Arizona Cancer Center Lecture Series - Green Valley.
- Gretzer, M. B. (2006, July). Prostate Disease. Green Valley Rotary Club. Green Valley, AZ.
- Gretzer, M. B. (2005, July). Erectile Dysfunction and the Prostate. American Urological Association Foundation Prostate Health Fair.
- Gretzer, M. B. (2005, July). Minimally Invasive Surgery for BPH. American Urological Association Foundation Prostate Health Fair.
- Gretzer, M. B. (2005, July). Prostate Cancer. UPH Hospital Community Presentation. Tucson, AZ.
- Kim, S., Hinkel, C., Coffey, D., Zohar, Y., Lee, B. R., & Gretzer, M. (2018, May). Fluid Dynamics and Morphology in the Obstructed Urethra. American Urological Association Conference. San Francisco: American Urological Association.
- Haney, N., Chiang, J., DeLay, K., Stewart, C., Yafi, F., Angermeier, K., Lacey, J., Wood, H., Boone, T., Kavanagh, A. G., Gretzer, M., Boyd, S., Doyle, J., & Hellstrom, W. (2017, March). Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional Analysis. Southeastern Section AUA 2017.More infoObjective: The impact of timing of radiation therapy for prostate cancer, whether given before or after artificial urinary sphincter (AUS) placement, is unknown.Objectives: The objective of this study was to determine if the timing of radiation therapy had an impact on AUS outcomes.
- Gretzer, M., Haney, N., Chiang, J., DeLay, K., Stewart, C., Yafi, F., Angermeier, K., Wood, H., Boone, T., Kavanagh, A. G., Boyd, S., & Doyle, J. (2016, October). Comparison of Adjuvant Radiation Therapy Before or After Artificial Urinary Sphincter Placement: A Multi-Institutional Analysis. Western Section AUA.More infoObjective: The impact of timing of radiation therapy for prostate cancer, whether given before or after artificial urinary sphincter (AUS) placement, is unknown.Objectives: The objective of this study was to determine if the timing of radiation therapy had an impact on AUS outcomes.